Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Dive Insight: Novo and rival Eli Lilly struggled to meet demand for their obesity drugs following their respective launches, forcing them to spend hundreds of millions of dollars to expand manufacturing of the complex, injectable peptide drugs
The dosage may vary depending on the brand and whether its being used for diabetes or weight loss
The value-based price (VBP) should reflect the monetized value of the health benefits (to patients), reduced medical spending and increased productivity associated with treatment
Children and Adolescents: BPC-157 has not been studied in pediatric populations
US$ 24.05
US$ 22.02
:format(webp))
US$ 28.19
